Abstract
To the Editor: Keratoacanthoma (KA) is a rapidly growing epidermal tumor. Although surgical resection is a primary option, several cases of KA have been successfully treated with topical imiquimod, a toll-like receptor agonist.1 However, no clinical study has evaluated its therapeutic efficacy. In this retrospective, single-center study, we described the results of topical imiquimod treatment for KA and clarified the factors affecting the response.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
